Print

Purpose

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant. - Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.

Exclusion Criteria

  • History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures. - Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator. - Other protocol-defined Inclusion/Exclusion criteria apply.

Study Design

Phase
Phase 1/Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Part 1A
  • Drug: BMS-986482
    Specified dose on specified days
Experimental
Part 1B1
  • Drug: BMS-986482
    Specified dose on specified days
  • Drug: Nivolumab and rHuPH20
    Specified dose on specified days
    Other names:
    • BMS-986298
Experimental
Part 1B2
  • Drug: BMS-986482
    Specified dose on specified days
  • Drug: Nivolumab/relatlimab/rHuPH20
    Specified dose on specified days
    Other names:
    • BMS-986213
Experimental
Part 1B3
  • Drug: BMS-986482
    Specified dose on specified days
  • Drug: Bevacizumab
    Specified dose on specified days
Experimental
Part 1C
  • Drug: BMS-986482
    Specified dose on specified days
Experimental
Part 2A
  • Drug: BMS-986482
    Specified dose on specified days
Experimental
Part 2B1
  • Drug: BMS-986482
    Specified dose on specified days
  • Drug: Nivolumab and rHuPH20
    Specified dose on specified days
    Other names:
    • BMS-986298
Experimental
Part 2B2
  • Drug: BMS-986482
    Specified dose on specified days
  • Drug: Nivolumab/relatlimab/rHuPH20
    Specified dose on specified days
    Other names:
    • BMS-986213
Experimental
Part 2B3
  • Drug: BMS-986482
    Specified dose on specified days
  • Drug: Bevacizumab
    Specified dose on specified days

Recruiting Locations

University of California, Irvine (UCI) Health - UC Irvine Medical Center
Irvine 5359777, California 5332921 92612
Contact:
Warren Chow, Site 0005
626-372-7121

The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles 5368361, California 5332921 90025
Contact:
Omid Hamid, Site 0030
310-231-2121

John Theurer Cancer Center at Hackensack University Medical Center
Hackensack 5098706, New Jersey 5101760 07601
Contact:
Martin Gutierrez, Site 0009
551-996-5863

Northwell Health/ RJ Zuckerberg Cancer Center
Lake Success 5123853, New York 5128638 11042
Contact:
Nagashree Seetharamu, Site 0007
917-574-8494

Levine Cancer Institute
Charlotte 4460243, North Carolina 4482348 28204
Contact:
Asim Amin, Site 0011
980-442-2000

Fred Hutchinson Cancer Center
Seattle 5809844, Washington 5815135 98109
Contact:
Cristina Rodriguez, Site 0010
206-288-6748

More Details

Status
Recruiting
Sponsor
Bristol-Myers Squibb

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
Clinical.Trials@bms.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.